HER2-CAR VSTs

HER2-CAR VSTs are autologous T cells engineered to express a chimeric antigen receptor (CAR) targeting the human epidermal growth factor receptor 2 (HER2), combined with virus-specific T cell (VST) properties. This dual-function cell therapy is designed to recognize and kill tumor cells expressing the HER2 antigen through MHC-independent mechanisms while retaining antiviral immune functions. The approach leverages the persistence and polyfunctionality of virus-specific memory T cells, potentially enhancing durability and safety compared to conventional CAR-T therapies. Preclinical studies have shown that these modified T cells efficiently lyse both tumor and virus-infected targets without harming healthy tissues. Clinically, HER2-CAR VSTs have been evaluated in phase I trials for progressive glioblastoma and other advanced solid tumors, demonstrating feasibility, safety (no dose-limiting toxicities), partial responses in some patients, and stable disease in others[1][3][5]. Ongoing research also explores their use in combination with oncolytic adenoviruses for synergistic antitumor effects[6].

Other names

HER2-specific CAR virus-specific T cellsHER-2-specific CAR virus-specific T cellsHER 2-specific CAR virus-specific T cellsHER2 CAR-VSTsHER-2 CAR-VSTsHER 2 CAR-VSTsHER2-specific autologous CAR VSTHER-2-specific autologous CAR VSTHER 2-specific autologous CAR VST